INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 417m ago
HOUSE PTR17m ago
SEC 13F17m ago
ROBINHOOD CHAIN17m ago
Corporate insider
SS

Sloan Sheldon

Chief Medical OfficerCIK 0002038798

EDGAR filingsOpen in network
Disclosed transactions10
Buys / sells0 / 7
Max Insider Score28
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
8
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$2.15M
78.3K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Spyre Therapeutics, Inc.Chief Medical Officer · Jan 13, 2026
27
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL
$1.48M
21.3K sh
May 1, 2026
May 1, 2026
traded May 1, 2026
+0d
SEC FORM 4

Evidence

27
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.39M
19.7K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

24
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$628K
8,777 sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

24
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$932K
12.8K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

28
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$764K
10.4K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

22
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$30K
400 sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

7
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
78.3K sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

28
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$377K
5,059 sh
May 1, 2026May 1, 2026
traded May 1, 2026
+0dSEC FORM 4

Evidence

9
SS
Sloan SheldonChief Medical Officer
SYRESpyre Therapeutics, Inc.
Grant or award
A—
140.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC FORM 4

Evidence